SecBot SecBot
SECBOTREPLAY Home › Report › PDSB

PDSB · PDS Biotechnology amended its $6M promissory note with YA II PN, Ltd.,…

PDS Biotechnology Corp · 8-K filed Sep 4, 2026 at 17:25 ET

At the news

BEARISHIMPACT 6/10

8-K filed Sep 4, 2026 at 17:25 ET

PDS Biotechnology amended its $6M promissory note with YA II PN, Ltd., tightening repayment terms: 100% of net proceeds from any non-ATM equity financing must be paid to the holder within 5 business days, and ATM proceeds are largely swept weekly. The Nasdaq listing deficiency cure period was extended from 75 to 180 days, signaling ongoing compliance risk. The amendment reflects severe liquidity constraints and limits the company's ability to retain capital from future equity raises.

  • Original promissory note principal: $6,000,000, issued June 15, 2026.
  • Amendment requires 100% of net cash proceeds from any non-ATM equity or equity-linked financing to be paid to the holder within 5 business days.
  • ATM net proceeds must be remitted weekly; excess over next installment is split 60% to holder / 40% retained by company.
  • Nasdaq listing deficiency cure period extended from 75 to 180 days.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access